Hadasit Bio-Holdings Ltd
OTC: HSITF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yuval Adar
- Employees
- 2
- Headquarters
- Jerusalem, Israel
- IPO year
- 2010
- Market cap
- $1.3M
- Website
- https://www.hbl.co.il
Loading HSITF…
Loading profile data…Frequently asked questions about HSITF
What does Hadasit Bio-Holdings Ltd (HSITF) do?
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.
Where does HSITF trade?
Hadasit Bio-Holdings Ltd (HSITF) trades on the Other OTC.
What sector is HSITF in?
Hadasit Bio-Holdings Ltd (HSITF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hadasit Bio-Holdings Ltd?
Yuval Adar is the chief executive officer of Hadasit Bio-Holdings Ltd (HSITF).
Where is Hadasit Bio-Holdings Ltd headquartered?
Hadasit Bio-Holdings Ltd is headquartered in Israel.
Does HSITF pay a dividend?
Hadasit Bio-Holdings Ltd (HSITF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HSITF go public?
Hadasit Bio-Holdings Ltd (HSITF) completed its initial public offering in 2010.